Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Miahelsa Holdings's average EBITDA Per Share Growth Rate was -7.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -2.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Miahelsa Holdings was -1.70% per year. The lowest was -2.40% per year. And the median was -2.05% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Miahelsa Holdings 3-Year EBITDA Growth Rate Related Terms
For the Pharmaceutical Retailers subindustry, Miahelsa Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Miahelsa Holdings 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Miahelsa Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Miahelsa Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -2.40% mean?
Miahelsa Holdings (TSE:7129) has a 3-Year EBITDA Growth Rate of -2.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Miahelsa Holdings and its competitors. According to the industry distribution chart, Miahelsa Holdings ranks #384 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 73%.
Is Miahelsa Holdings' 3-Year EBITDA Growth Rate too high?
Miahelsa Holdings' current 3-Year EBITDA Growth Rate is -2.40%. Based on the distribution chart, Miahelsa Holdings ranks #384 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Miahelsa Holdings has a GF Score™ of 42/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Miahelsa Holdings' 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Miahelsa Holdings ranks #384 out of 526 companies for 3-Year EBITDA Growth Rate. This places Miahelsa Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Miahelsa Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Miahelsa Holdings's current 3-Year EBITDA Growth Rate is -2.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Miahelsa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Miahelsa Holdings (TSE:7129) is currently considered Fairly Valued. The stock's GF Value™ is 円1,089.37, compared to a current price of 円1,170.00 — trading 7.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -2.40%. Miahelsa Holdings' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Miahelsa Holdings (TSE:7129), the current 3-Year EBITDA Growth Rate is -2.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Miahelsa Holdings (TSE:7129) Overvalued in 2026?
Based on GuruFocus' analysis, Miahelsa Holdings stock appears to be overvalued.
The current stock price of 円1,170.00 is trading 7.4% above its estimated GF Value™ of 円1,089.37.
GuruFocus considers Miahelsa Holdings to be Fairly Valued.
Key valuation signals for TSE:7129:
3-Year EBITDA Growth Rate: -2.40%
GF Value™: 円1,089.37 vs. price of 円1,170.00 (7.4% above fair value)
No single metric tells the full story. See the TSE:7129 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Miahelsa Holdings Corp, along with its subsidiaries, operates in the following reportable segments: Pharmaceutical Business, Nursing Care Business, and Childcare Business. The majority of its revenue is generated from the Pharmaceuticals Business, which operates pharmaceutical dispensaries in Japan through Nissei Pharmacy and Miahelsa Pharmacy brands, and also offers home care services. The Nursing care business mainly provides housing, medical care, nursing care, prevention, and lifestyle support for elderly people, and the Childcare segment involves the operation of licensed childcare centers. In addition, the group also operates a food business providing food suitable for all ages, from infants to the elderly.
42GF Score
Get the complete analysis for TSE:7129
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7129 has been successfully added to your 
